source
- Biokin's EGFR-HER3 bispecific ADC succeeds in late-stage Chinese lung cancer trialChinese biotech Biokin announced that its EGFRxHER3 bispecific antibody-drug conjugate met its primary endpoint in a late-stage trial in a genetically defined subset of non-small cell lung cancer (…
- Federal appeals court revives portion of Teva's Medicare price-negotiation lawsuit amid Austedo discount plansFederal appeals court in the D.C. Circuit issued a decision Tuesday that partially overturns a lower‑court ruling that had dismissed Teva's challenge to Medicare's drug pricing negotiations. The r…